Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Advances in Urology is Scopus-indexed (Q2, CiteScore 3.2), WoS ESCI, DOAJ. Published by John Wiley and Sons Ltd.
Checked against the index lists dated .
ISSN 1687-6369Verify ISSN ↗1687-6377Verify ISSN ↗
Publisher: John Wiley and Sons Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Obstetrics and Gynecology | 97 / 218 | 55th | Q2 |
| Urology | 56 / 123 | 54th | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2009–present, best quartile Q2, CiteScore 3.2.
Advances in Urology is Q2 in Obstetrics and Gynecology (rank 97 of 218) and Q2 in Urology (rank 56 of 123), by CiteScore 2025.
Advances in Urology is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.2, which places it in quartile Q2 at the 55th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.290, quartile Q3, with an H-index of 42.
The publisher lists an article processing charge of about US$1,000 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Advances in Urology is published by John Wiley and Sons Ltd. Its print ISSN is 1687-6369 and its online ISSN is 1687-6377.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Advances in Urology has an h-index of 49 and a 2-year mean of 0.56 citations per paper (OpenAlex). Its Scopus CiteScore is 3.2, quartile Q2. On 2-year citations it ranks #142 of 210 Scopus journals in Obstetrics and Gynecology.
Advances in Urology published 11 papers in 2025; its busiest recent year was 2018 with 28. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 92 research articles (2021–2026), authors are most often from Japan (18.5%), China (10.9%) and United States (8.4%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (3.6 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.